News

Select Press Release & News

November 18, 2024
Press Release: Exo Therapeutics Presents Data on Novel Exosite Inhibitors of TBK1 (EXO-TBKi) Shown to Disrupt Pathological STING-mediated TBK1 Activation at American College of Rheumatology’s Convergence (ACR)

October 22, 2024
Press Release: Exo Therapeutics Announces Late Breaking Poster at American College of Rheumatology’s Convergence (ACR)

July 2, 2024
Poster: A Novel Exosite Inhibitor that Selectively Reprograms TBK1-STING Pathway for Autoimmune Diseases

June 20, 2024
Press Release: Exo Therapeutics Presents Key Data at FOCIS 2024 Demonstrating the Efficacy of Potent and Selective Exosite-targeted TBK1/STING Inhibitor in Multiple Preclinical Models

May 23, 2023
Press Release: Exo announces lead program, targeting TANK Binding Kinase 1 (TBK1), for the treatment of autoimmune diseases &
Appointment of Alexandra Joseph, PhD, as Executive Vice President of Biology

January 4, 2023
Press Release: Exo Therapeutics Appoints Nagesh Mahanthappa as Executive Chair

November 4, 2022
News: 10 Start-ups to Watch

November 1, 2022
Press Release: Exo Therapeutics Announces Promotion of Dorothy Lou Bailey to Chief Operating Officer and Interim President

May 27, 2022
News: Up and down the ladder: The latest comings and goings

May 17, 2022
Press Release: Exo Therapeutics Appoints Stephanos Ionnadis as Executive Vice President, Drug Discovery

April 26, 2022
Press Release: Exo Therapeutics Appoints Laura Kiessling to Scientific Advisory Board

October 26, 2021
Press Release: Exo Therapeutics Appoints Dorothy Lou Bailey as Senior Vice President, Corporate Development and Strategy

October 5, 2021
News: Novartis-backed Exo Therapeutics secures $78M to reprogram enzymes sans side effects

October 5, 2021
Press Release: Exo Therapeutics Raises $78 Million Series B Financing

March 30, 2021
Press Release: Exo Therapeutics Appoints Nagesh Mahanthappa to Board of Directors and Charles W. Roberts to Scientific Advisory Board

December 16, 2020
Press Release: Exo Therapeutics Launches with $25 Million Series A Financing to Unlock Intractable Drug Targets with Exosites

July 23, 2020
Press Release: A startup emerging from David Liu’s lab intends to commercialize a small-molecule enzyme inhibitor discovery platform to generate more potent drugs with higher specificity.

We are a diverse group of scientists, researchers, and business leaders with the mission to develop a novel approach to medicines discovery with exosites.